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 ABSTRACT 
The biodegradable polymers like poly lactic acid (PLA) and poly (lactide-co-glycolic 
acid) (PLGA) are considered as the „green‟ eco-friendly materials due their biocompatibility 
and non-toxic properties. Biodegradable microspheres and nanoparticles have proven to be 
very useful in protein and DNA delivery systems. These are easily taken up by 
immunocompetent cells, shows prolonged antigen release characteristics and provide a long 
lasting immunity. Micro and nano-particulate based protein and DNA delivery systems have 
its importance for various therapeutic and biomedical applications. PLA and PLGA 
microparticles and nanoparticles were formulated by double solvent emulsion evaporation 
(w/o/w) method and characterised for their surface morphology, size, loading efficiency and 
release profile study. The microsphere and nanosphere morphology were examined by SEM 
and Zeta sizer. It was found that PLA encapsulated with BSA (2.5%) showed loading 
efficiency more than 82% and that with plasmid DNA (Concentration: 1mg/ml), it was found 
to be 41%. It was also found that the particle size for PLA was varying between 162-373 nm. 
Similarly for PLGA particles when encapsulated with BSA, the loading efficiency became 
91% whereas for encapsulated plasmid DNA, the loading efficiency was 44%, with their 
respective particle size between 113-335 nm. In vitro release of BSA and plasmid DNA from 
encapsulated PLA and PLGA nanoparticles were checked spectrophotometrically with 
optical density 562 nm for protein and 260 nm in case of plasmid DNA, by taking samples at 
different time intervals dissolved in PBS (phosphate saline buffer, at pH 7.4). 
 
 
Key Words: PLA, PLGA, BSA, SEM, nanosphere, microsphere, in vitro. 
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INTRODUCTION 
Vaccines are very effective means to control or eradicate microbial transmissible 
diseases, and also effective for immunotherapeutic point of view. There are some 
difficulties associated with certain vaccines such as: (i) the requirements of multiple 
injections schedule primary immunization followed by periodic boosters as required 
maintaining immunity. (ii) A short product shelf life at room temperature requiring 
refrigeration. (iii) The induction of a biased immune response towards the humoral 
system. These are not optimal for many applications such as intracellular viral, bacterial 
and parasitic infections as well as tumour immunotherapy. So, new antigen delivery 
technologies are essential to fulfil some of these limitations. 
Modern vaccinology emphasises on sub unit immunogens or related nucleic 
acids. These vaccines primarily consist of proteins or polysaccharide antigens and the 
related DNA, RNA or oligonucleotides from the target pathogen. We need delivery 
system for the delivery of antigens. A delivery system for antigens and vaccine DNA 
may be defined as the pharmaceutical formulation that enhances or facilitates the action 
of antigen or vaccine by delivering, ideally the correct amount of antigen or vaccine to 
the site of action at the correct rate and timing, in order to maximize the immunological 
response and minimize the undesired effects. In a more extended definition, antigens and 
DNA vaccine delivery system may also encompass the controlled release of specific 
maturation stimuli for the antigen presenting cells. Thus it can be derived from these 
definitions that a delivery system for antigen and vaccine DNA is a modern and 
sophisticated form of an adjuvant with engineered immunological properties. 
Polymeric micro and nanoparticles, as well as colloidal lipid and surfactant-based 
particulate delivery system, play an increasing role in vaccine development. Besides 
exhibiting adjuvant properties, some of these particulate systems are also designed to 
deliver the antigen or related nucleic acid in a controlled, sustained manner, so that fewer 
injections are needed to provide a fully protective response. DNA delivery system for 
vaccines has a strong emphasis on biodegradable micro and nanospheres, in addition to 
virosomes and immune stimulating complexes, all of which posses high potential as both 
preventive and therapeutic vaccines for parenteral, nasal and possibly oral administration. 
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Nanoparticulate delivery systems, such as those based on poly (lactic-co-glycolic 
acid) (PLGA) and poly (lactic acid) (PLA) polymers, have been studied since many 
years. For the past three decades, lots of work has been done to utilize biocompatible and 
biodegradable polymers for drug delivery systems. PLGA and PLA polymers have the 
advantage of being well characterized and commercially used for microparticulate and 
nanoparticulate drug delivery systems (Allemann and Leroux, 1999). PLGA and PLA 
polymers are biocompatible, biodegradable. Polymeric nanoparticles are widely use as 
pharmaceutical dosage form of proteins and peptides. Many methods are recently applied 
for the preparation of polymeric nanoparticles, such as emulsification–evaporation 
method, salting-out procedure and nanoprecipitation method. Nevertheless, several 
difficulties have been found for adopting these methods. The usage of solvent may cause 
toxicity, stabilizers such as polyvinyl alcohol (PVA) cannot be accepted for intravascular 
usage, and the salts are incompatible with bioactive compound. 
 
Poly (lactic acid) (PLA): 
Fully biodegradable synthetic polymers have been available since many years, 
such as poly (lactic acids) (PLA). Among all biopolymers, PLA was extensively studied 
in medical implants, suture, and drug delivery systems since 1980s due to its 
biodegradability (fig. 2). The structure of PLA polymer is given in fig. 1. 
 
                          Fig. 1:  Structure of Poly lactic-acid; n- no of chains 
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Fig. 2: NTS (Nanotechsystems inc.) utilizes polylactic acid (PLA) based nano particles 
that have been formulated to encapsulate a drug, allowing for an intracellular site of 
action. In this case, the drug binds to the cytoplasmic receptors and the subsequent drug-
receptor complex is transported to the nucleus resulting in the expression of the drug 
product. 
 
Poly (lactic-co-glycolic acid) (PLGA): 
Over the past few decades, biodegradable polyesters, such as poly (lactic acid) 
(PLA) and poly (lactic-co-glycolic acid) (PLGA), have been extensively studied for a 
wide variety of pharmaceutical and biomedical applications. The biodegradable polyester 
family has been regarded as one of the few synthetic biodegradable polymers with 
controllable biodegradability, excellent biocompatibility, and high safety. Among these 
polyesters PLGA plays an important role in drug delivery system. The structure of PLGA 
as given in fig. 3. 
           
Fig. 3: Structure of poly (lactic-co-glycolic acid). x= number of units of lactic 
acid; y= number of units of glycolic acid. 
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Poly (lactic-co-glycolic acid) have also been called poly (lactide-co-glycolide), 
according to the nomenclature system based on the source of the polymer. Although the 
name was used in many references in the past, a recent trend is to follow the 
nomenclature system of the International Union of Pure and Applied Chemistry (IUPAC) 
that is based on the repeating unit structure. PLGA can be degraded into non-toxic 
substances and removed from the human body. Accordingly, they have taken centre 
stages in a variety of research efforts. 
Biodegradable poly (lactic-co-glycolic acid) (PLGA) and poly (lactic acid) (PLA) 
polymers show interesting properties for biotechnology through their biocompatibility 
and their authorization by the Food and Drug Administration (FDA) for drug delivery. 
Various polymeric drug delivery systems like microparticles or nanoparticles have been 
developed using these polymers for the delivery of a variety of drugs (Jain, 2000). 
However, the technology processes often use organic solvents to dissolve the water-
insoluble PLGA. Usually, halogenated solvents, such as methylene chloride and di-
chloro methane are used in the microencapsulation process. 
OBJECTIVES: 
1. To prepare microparticles and nanoparticles based drug delivery system using natural 
polymer (PLA and PLGA) with biocompatible properties. 
2. Formulation and evaluation of protein and DNA delivery system using PLA and 
PLGA nanoparicles and microparticles. 
3. Protein (Bovine Serum Albumin) was taken from Sigma chemicals and plasmid DNA 
(E. coli) was purified, encapsulated into these polymer particles. 
4. Characterization of prepared nanoparticles and microparticles like measurement of 
encapsulation efficiency, release study and surface characterization by SEM.  
5. To prepare an efficient oral, intranasal and intramuscular drug delivery system using 
these biodegradable PLA/PLGA nanoparticles. 
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REVIEW OF LITERATURE 
Biodegradable particles (0.1–1.5µm) prepared from poly(lactide-co-glycolide) 
(PLGA) and poly(lactic acid) (PLA) polymers have generated considerable interest in 
recent years for their use as a delivery vehicle for various pharmaceutical agents. 
According to Perrin and English, (1997) these polymers are the most common 
biodegradable polymer used for the controlled delivery of drugs due to its early use and 
approval as a compatible biomaterial in humans. Lewis, (1990) reported that, by varying 
the molecular weight and lactide /glycolide ratio, the degradation time of the PLA and 
PLGA and the release kinetics of the active agent can be controlled. 
The multiple emulsion-solvent evaporation technique being used for preparation 
of PLGA and PLA nanoparticles is believed to produce heterogeneous size distribution. 
Various formulation factors and characteristics of the nanoparticles have a key role to 
play in biological applications like drug delivery systems. The foremost factor that could 
have an influence on the transfection and cellular uptake is the size of the nanoparticles. 
Prabha et al., (2002) have studied the size-dependency of nanoparticle-mediated gene 
(plasmid DNA) transfection with fractionated nanoparticles. Recent reports suggests that 
a fraction of the stabilizer PVA always remains associated with the nanoparticles despite 
repeated washings because PVA forms an interconnected network with the polymer at 
the interface. We came across similar factors while formulating nanoparticles using PVA 
as a stabilizer. Above all, the stability and biological activity of the plasmid have been 
major concerns due to the involvement of organic solvents during the preparation 
process. 
 
Formulation of PLA and PLGA polymeric particles: 
Lemoine et al., (1996) reported that, biodegradable colloidal particles have 
received considerable attention as a possible means of delivering drugs and genes by 
several routes of administration. Special interest has been focused on the use of particles 
prepared from polyesters like PLGA, due to their biocompatibility and resorbability 
through normal bioprocesses of the body. Various methods have been reported for 
making nanoparticles viz., emulsion-evaporation (Gurny et al., 1981), salting-out 
technique (Allemann et al., 1992), nanoprecipitation (Fessi et al., 1989), cross-flow 
filtration (Quintanar-Guerrero et al., 1998) or emulsion-diffusion technique  
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(Choi et al., 2002 and Niwa et al., 1993). Indeed PLGA particles are extensively 
investigated for drug (Schachter and Kohn, 2002 and Lamprecht et al., 2001) and gene 
delivery (Cohen-Sacks et al., 2002 and Prabha et al., 2002), but still improvements in the 
existing methods are needed to overcome the difficulties in terms of reproducibility, size, 
and shape. The size and shape of the colloidal particles are influenced by the stabilizer 
and the solvent used. Most investigated stabilizers for PLGA lead to negatively charged 
particles and the plasmid incorporation is achieved via double emulsion technique during 
particle preparation. This could generate problems in the stability and biological activity 
of the plasmid due to the involvement of organic solvents during the preparation 
processes. This can be overcome by using cationically modified particles that can bind 
and condense negatively charged plasmids by simply adhering / encapsulating  the 
plasmid or vice versa. Vandervoort and Ludwig. (2002), suggested that PVA as most 
popular stabilizer for the production of PLGA nanoparticles leading to negatively 
charged particles, nevertheless, investigations have been carried out using other 
stabilizers as well. 
 
 PLA and PLGA Particles in Protein Delivery: 
  According to Bittner et al., (1998), PLGA has a negative effect on protein 
stability during the preparation and storage, primarily due to the acid-catalyzed nature of 
its degradation. Its hydrolysis leads to the accumulation of acidic monomers, lactic and 
glycolic acids within the drug delivery device, thereby resulting in a significant reduction 
of pH of the microenvironment and denaturation of the encapsulated proteins. In 
addition, processing conditions used in the manufacturing of PLGA drug delivery 
vehicles have detrimental effects on certain protein secondary structures (Johansen et al., 
1998). 
For encapsulating peptide or protein using PLGA NPs/MPs, mainly three 
methods are used: water–oil–water (w/o/w) emulsion technique, phase separation 
methods and spray drying (Freitas, 2005). Peptides or proteins are either dispersed in an 
organic solution of PLGA or preferably processed in an aqueous solution of water-in-oil 
(w/o) emulsion. The dispersion step is carried out using high speed sonicator. 
Raghavendra et al., (2008), reported that, MPs are produced by either extracting 
organic solvent or by adding a non-solvent i.e., silicone oil, thereby inducing 
coacervation. The first process is frequently referred as w/o/w method, while the latter 
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is known as the phase separation technique. In both the cases, particle formation occurs 
in the liquid phase. In spray drying technique, particle formation is achieved by 
atomizing the emulsion into a stream of hot air under vigorous solvent evaporation. 
Different methods are schematically displayed in Fig: 4. 
 
 
 
Fig. 4: Comparison of microencapsulation methods: (i) solvent evaporation, (ii) polymer 
phase separation and (iii) spray drying. Aqueous solution is dispersed in the organic 
polymer solution by ultrasonication (w/o) emulsion; the w/o emulsion is processed further 
by specific methods to prepare the drug-loaded microparticles 
 
According to Raghavendra et al., (2008), proteins encapsulated by w/o or w/o/w 
techniques into NP or MP are susceptible to denaturation, aggregation, oxidation and 
cleavage, particularly at the aqueous phase-solvent interface. Protein denaturation may 
also result in a loss of biological activity. Improved protein integrity has been achieved 
by the addition of stabilizers such as carrier proteins (e.g., albumin), surfactants during 
the primary emulsion phase or molecules such as trehalose and mannitol to the protein 
phase. Protein stability may also be enhanced if the protein is encapsulated as a solid 
rather than in solution. It should be noted that all the nano/micro-encapsulation 
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techniques create mechanical, thermal and chemical stresses on the system under 
investigation.  
 
 
PLA and PLGA Particles for Plasmid DNA Delivery: 
Biodegradable poly (lactide) (PLA) or poly (lactide-co-glycolide) (PLGA) 
microparticles and nanoparticles were demonstrated to represent a potent delivery 
platform for DNA vaccines (Johansen et al., 2000). When embedded in biodegradable 
polymeric particles, encapsulated plasmid DNA can be protected from enzymatic 
degradation and released in a controlled manner, mimicking conventional vaccines 
(Thomasin et al., 1996). 
According to Niidome and Huang (2002), plasmid DNA delivery by physical 
methods generally results in low but sustained expression in vivo, which is limited by 
poor uptake due to factors such as degradation and clearance.  
Herweijer and Wolff (2003), reported that,   physical methods (e.g., ultrasound, 
hydrodynamic injection) are continually being improved to enhance cellular uptake of 
DNA by altering cell permeability. Intrinsic cellular processes may be involved due to 
plasmid uptake, but the processes governing intracellular transport remain elusive. 
Following delivery to the nucleus, expression can typically occur over time scales of 
days to weeks or months. Extracellular factors that limit delivery include plasmid 
clearance or degradation, which can be mediated by sequence-specific recognition from 
the immune system. Immune responses to the plasmid are affected by the methylation 
pattern of CpG sequences that can affect the duration of transgene expression.  
Beginning in the 1980s, various groups could demonstrate that intramuscular 
injection of plasmid DNA led to its transcription in myocytes resulting in the secretion of 
the encoded protein (Benevisty and Rashef, 1986; and Wolff et al., 1990). Then Tighe et 
al., (1998) and Srivastava and Liu (2003) reported that, specific antibodies against the 
encoded proteins related to the Th1 pathway were found in the serum of the vaccinated 
animals. Using diverse delivery routes (intramuscular, intradermal, subcutaneous or 
oral), a variety of animal models and various doses of DNA, it was shown that DNA 
vaccination can be efficient to concomitantly induce Th1 immune response with antibody 
production and cytotoxic T lymphocyte (CTL) response (Jilek et al., 2005). 
Ledley (1996), reported that, polymeric delivery represents an alternative 
approach that can increase residence time within the tissue and protect against 
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degradation. Plasmids (10
3–104 bp) have effective hydrodynamic diameters in excess of 
100 nm and a highly negative surface charge density. The large size of the DNA limits  
transport through tissues, resulting in diffusion coefficients on the order of 10
- 9
 to 10
- 12
 
cm
2
/s (Zaharoff et al., 2002), and promotes localized delivery when polymers are 
inserted into a tissue (Bajaj and Andreadis, 2001). 
 
In vitro Release study 
Biodegradable microparticles prepared from PLA or PLGA have been studied for 
their controlled release properties for more than a decade (Johansen et al., 2000). Their 
main advantages for this purpose are their technical versatility, biocompatibility and 
biodegradability (Berkland et al., 2002 and Berkland et al., 2003). Indeed, various 
parameters such as polymer composition, size or surface properties can be customized to 
achieve a distinct polymer erosion profile in order to control the release of the 
encapsulated therapeutics (Walter et al., 1999). 
Plasmid DNA interacts weakly with many polymers leading to in vitro release 
from the vehicle with rates modulated by the polymer properties. Many synthetic and 
natural polymers are negatively charged, and thus the weak interactions likely result from 
repulsive charge interactions between plasmid and polymer. 
According to Ochiya et al., (2001) and Shea et al., (1999), controlled release 
systems typically employ polymeric biomaterials that deliver vectors according to two 
general mechanisms: (i) polymeric release, in which the DNA is released from the 
polymer, or (ii) substrate-mediated delivery, in which DNA is retained at the surface. For 
polymeric release, DNA is entrapped within the material and released into the 
environment, with release typically occurring through a combination of diffusion and 
polymer degradation.  
Cleland et al., 1997 and Thomasin et al., 1996, reported that PLGA MS can 
provide antigen release over weeks and months following continuous or pulsatile 
kinetics. It was hoped that the pulsatile antigen release would mimic the booster doses 
necessary with most other nonlive vaccines (Aguado and Lambert, 1992) by controlling 
polymer properties (Kissel et al., 1997) and due to the fact that PLGA MS are readily 
recognised and ingested by macrophages and dendritic cells, an important property for 
stimulating the immune system (Walter et al., 2001). 
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A major problem hindering the progression of MS based vaccine formulations for 
human use is the issue of antigen stability during microencapsulation, storage and release 
(Hanes et al., 1997 and Uchida et al., 1996). Nonetheless, means to retain and maintain 
antigen stability and immunogenicity have been proposed (Johansen et al., 1998; 
Sanchez et al., 1999 and Lee et al., 1997). Consequently, this review will focus on in 
vitro antigen stability and release issues, with an attempt to elaborate on some of the 
different approaches and strategies employed to overcome these limiting factors. 
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OBJECTIVES 
 
 To formulate an efficient drug delivery system using natural polymers (PLA and 
PLGA) to enhance the release and stability of plasmid and protenaceous drugs. 
 To protect the protein and DNA property from degradation with the addition of 
stabilizer. 
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PLANS OF WORK                                                                                                .   
                     
Preparation of PLA and PLGA microparticles/nanoparticles 
↓↓ 
Loading bovine serum albumin (BSA) and plasmid DNA to PLA and PLGA 
microparticles/nanoparticles 
↓↓ 
Calculation of LC (Loading efficiency) 
using BCA protein estimation method 
↓↓ 
Study of in-vitro release of protein and DNA from PLA and PLGA particles 
↓↓ 
Measurement of particle size and zeta potential using Zeta sizer 
↓↓ 
Morphological characterization by using scanning electron microscope (SEM) 
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MATERIALS AND METHODS 
MATERIALS 
 Poly(L-lactic)acid (PLA)[ Sigma-Aldrich] 
 Poly(lactic-co-glycolic acid) (PLGA) [Sigma- Aldrich]  
 Bovine serum albumin fraction –V(HiMedia)  
 Poly vinyl alcohol(PVA) [Sigma-Aldrich]  
 BCA™ protein estimation kit  
 Ultrapure water from Milli-Q water system. 
EQUIPMENTS 
 Stratos low-temperature high-speed centrifuge(Thermo, Germany) 
 Cooling centrifuge (REMI) 
 Freeze Dryer (Lab Tech) 
 Magnetic stirrer 
 Sonicator 
 Zeta sizer (Malvern) 
 Scanning electron microscope 
 Fourier transform infra-red (FTIR)  
 Gel electrophoresis unit (Biorad) 
 Gel documentation system (BioRad) 
METHODS: 
Isolation of plasmid DNA from E. Coli 
The plasmid was isolated from E.coli. Primary culture was done in Maconkey agar 
medium then the culture was transferred to Luria Bertni broth medium and kept in shaker 
incubator for 48 hours at 37
o
C. Then plasmid was isolated from the culture by mini 
preparation method following steps. 
 First 1.5 ml culture was transferred in to 1.5 ml eppendrof tube. 
 Then centrifuge was done at 11,500 rpm for 5 mins at 4oC. 
 After centrifugation the supernatant was removed by decanting. 
 The pellet was resuspended in the little (20-30µl) remaining supernatant by vortex. 
 300µl of TENS (at 370C) was added and vortex vigorously for 30 seconds. 
 150µl of 3M Sodium acetate (pH- 5.2), was added at RT and vortex for 30 sec. 
 Centrifuge was done at 12,000 rpm for 5 mins at 4oC. 
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 The supernatant was then transferred to a clean 1.5 ml eppendorf tube (300µl). 
 1 ml absolute ethanol (100%) was added and mixed gently by inverting partially (only 
once). 
 Centrifuge was then done at 12,000 rpm for 5 mins at 4oC. 
 Absolute (100%) ethanol was removed by aspirator. 
 700µl of 70% ethanol was added. 
 Then centrifuge was done with 12,000 rpm for 5 mins at 4oC. 
 All the ethanol was removed carefully by an aspirator. 
 White smear was seen in the tube and marked it. 
 Then the pellet was allowed to dry. 
 25µl of TE was added in the tube. 
 Then the culture was stored at -20oC. 
Phenol chloroform extraction 
 Plasmid DNA (25µl) was diluted with 200µl of TE buffer. 
 200µl of Phenol: Chloroform: Isoamyl alcohol (25:24:1) was added and vertex for 20 
sec. 
 Then centrifuge was done with 12,000 rpm for 6 mins at 4oC. 
 Upper aqueous phase (300µl) was taken into another fresh 1.5 ml eppendorf tube. 
 30µl of 3M Sodium acetate and 800µl of absolute (100%) ethanol was added. 
 Then the tube was kept in -20oC for 2 hours. 
 Centrifuge was done with12, 000 rpm for 25 mins at 4oC. 
 Absolute (100%) ethanol was removed by aspirator without touching the DNA. 
 500µl of 70% ethanol was added then centrifuged at 12,000 rpm for 12 mins at 4oC. 
 Then ethanol was aspirated carefully, marked the pellet, dried and dissolved in 25µl of 
TE buffer.  
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DESCRIPTION OF SAMPLES WITH THEIR RESPECTIVE COMPOSITIONS 
Table-1: Description about  PLA samples with different compositions. 
Sl.No Sample 
Name 
PLA 
(mg) 
DCM 
(ml) 
IAP EAP  
(ml) 
Conc
n
. 
(OP:IAP) 
BSA 
+ 
Sucrose 
(µl) 
Plasmid  
(µl) 
1 101 
(Normal) 
200 4 _ _ 16 _ 
2 102 200 4 800 _ 16 1:5 
3 103 200 4 500 _ 16 1:8 
4 104 200 4 400 _ 16 1:10 
5 105 125 2.5 _ 1000 10 1:2.5 
6 106 125 2.5 _ 500 10 1:5 
7 107 125 2.5 _ 250 10 1:10 
 
       Table-2: Description about  PLGA samples with different compositions.  
Sl. No Sample 
Name 
OP IAP EAP 
(ml) 
Conc
n
. 
(OP:IAP
) PLGA 
(mg) 
DCM (ml) BSA + 
Sucrose (µl) 
Plasmid 
(µl) 
1 201 200 4 _ _ 16 _ 
2 202 200 4 800 _ 16 1:5 
3 203 200 4 500 _ 16 1:8 
4 204 200 4 400 _ 16 1:10 
5 205 125 2.5 _ 1000 10 1:2.5 
6 206 125 2.5 _ 500 10 1:5 
7 207 125 2.5 _ 250 10 1:10 
[PLGA: Poly (lactide-co-glycolic acid, OP: Organic Phase, DCM: Dichloromethane, 
BSA: Bovine Serum Albumine (2.5%), Plasmid DNA: Final concentration is 1mg/ml, 
IAP: Internal Aqueous Phase, EAP: External aqueous phase] 
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Preparation of Protein and DNA loaded PLA and PLGA Particles 
PLA and PLGA particles were prepared using double solvent evaporation method  as 
given in fig. 5. The details description of different phases in particles formulation as 
given in table- 3. 
 
Table-3: General description of materials in particles formulation. 
 
 
 
 
 
 
 
 Polymer was dissolved in organic phase (4ml) then, sonicated with addition of IAP to 
make primary emulsion. 
 For the formation of secondary emulsion 16 ml of EAP was added drop wise manner 
into the primary emulsion during sonication of primary emulsion. 
 Then the secondary emulsion was kept in magnetic stirrer for overnight for excess 
DCM to evaporate. 
 Particles were separated through centrifugation at 15000 rpm for 20 mins. 
 Separated particles were washed twice with ice cold MQ water then particles were 
lyophilized to obtain dry particles and stored in -20
o
C for further use.  
Same methodology was followed in case of plasmid DNA loaded particle formation, 
but 10ml of EAP was used instead of 16ml and there was no use of sucrose and sodium 
bicarbonate in IAP. The systematic representation of solvent evaporation method was 
given in fig. 6. 
 
 
 
Condition IAP OP EAP 
 
Protein (BSA) 
 
BSA (2.5%) 
NaHCO3 (2%) 
Sucrose (10%) 
PLA/PLGA (200mg) 
DCM (4ml) 
PVA (1%) 
Plasmid DNA Plasmid DNA 
(1mg/ml) 
PLA/PLGA (125mg) 
DCM (2.5 ml) 
PVA (1%) 
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Preparation of nanoparticles 
(Double emulsion-solvent evaporation method) 
                                                         IAP                                         OP 
                                                                                       (Polymer + DCM)    
 
 
 
 
                                                                                      Sonication 
 
 
 
                                                                                                  First Emulsion 
 
 
 
 
 
                                                                                                 Addition of EAP 
                                                                                                     (Sonication) 
 
 
                                                                                                  Secondary Emulsion 
 
 
                                                                                                  Keep the Samples in Magnetic   
                                                                                                    Stirrer for overnight then    
                                                                                                  Centrifuge at 15000 rpm for  
                                                                                                                 20 mins                                                      
                                                 
 
                                                                                                   Wash with MQ Water then 
                                                                                                        Allow to freeze dry 
 
 
 
 
 
                                                   Particle size was analyzed by Zeta Sizer 
 
 
Fig. 5: Solvent evaporation method for the preparation of PLA and PLGA nanoparticles 
 
 
 
Emulsion Solvent Evaporation Method 
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               ORGANIC PHASE                                                INTERNAL AQUEOUS PHASE 
          (Polymer + Dichloromethane)                                     (DNA/BSA + MQ Water) (W1) 
 
 
                                                                                         
                                                                                                 Emulsification (Sonication) 
 
 
 
                PRIMARY EMULSION                                        WATER + POLY VINYL  
                            (W1/O)                                                               ALCOHOL (W2)   
   
                                       
 
                                                                                                   Emulsification 
                                                                                                     (Sonication) 
 
 
                                                     SECONDARY EMULSION 
                                                                  (W1/O/W2) 
                                                                                                   
                                                                                                  DCM 
                                                                                                   
                                                                                          (Centrifugation) 
                                                               
                                                        NANOPARTICLES AND 
                                                            MICROPARTICLES 
 
 
                                                      
                                                     LYOPHILIZED TO RECOVER  
                                                               THE PARTICLE 
 
 
    Fig. 6: Preparation of Nano and Microparticles by Emulsion Solvent Evaporation  
                Method    
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Estimation of protein (BSA) and plasmid DNA encapsulation efficiency 
The encapsulation efficiency or loading efficiency of PLA and PLGA particles 
was calculated by spectrophotometrically (at OD 562nm). While separating the particles 
by centrifugation the supernatant was collected and analysed by spectrophotometer. The 
amount of DNA in the supernatant was substracted from the amount used in IAP. This 
amount was used for the calculation of entrapment efficiency. Then the loading 
efficiency of protein (BSA) was calculated by BCA method (Biocinchroninic acid 
protein assay). 
 
Where LE = Loading efficiency 
 
In vitro release of encapsulated protein and DNA 
In vitro release studies of prepared nanoparticles were carried out at 37°C. 
Approximately 10 mg of nanoparticles were suspended in 1 ml of PBS (phosphate saline 
buffer, pH 7.4) taken in 1.5ml eppendorf placed in incubator shaker for the period of 
study (200 rpm at 37°C). Then the samples were collected periodically after 
centrifugation at 13000 rpm for 20mins. Then the supernatant was collected and the 
amount of protein (BSA) released was estimated by BCA™ kit using spectrophotometer. 
Similarly for plasmid DNA released was determined by spectrophotometrically. Then the 
pellet was reconstituted, resuspended in 1ml fresh PBS and kept in shaker for further 
sampling. The systematic representation of release study for encapsulated particles as 
shown in fig. 7.  
 
 
 
 
Release study from PLA and PLGA Particles 
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   PARTICLES CONTAINING                                                   PBS (pH 7.4, 50mM) 
       BSA/PLASMID DNA                                                                    (500µl) 
 
 
 
                                           SAMPLE EPPENDORF WERE KEPT  
                                                  IN INCUBATOR SHAKER  
                                                                                        (After specific interval) 
                                                                                    
                                                   SAMPLES WERE REMOVED  
                                                          AND CENTRIFUGED    
                                                           (13000rpm, 10 mins) 
 
 
 
                 
                                                            PELLET                                        SUPERNATANT 
                                                       +        
                                              FRESH PBS    
                 
 
 
                                KEPT IN INCUBATOR                        ESTIMATION FOR RELEASED 
                     SHAKER FOR FURTHER USE                                   PROTEIN/DNA  
                               (37
O
C, 200rpm)                                        SPETROPHOTOMETRICALLY   
   
 
                   Fig. 7: Release Study of Protein/DNA for PLA and PLGA Nanoparticles          
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Particle Size and Surface Characterization : 
10mg of the lyophilized polymer particles were redispersed in 10ml of MQ water, 
sonicated in water bath for 15 mins and the size was measured in Zeta sizer (Malvern). 
For surface morphology characterization, lyophilized particles were examined by 
scanning electron microscope (SEM). For SEM, a specimen is normally required to be 
completely dry, since the specimen chamber is at high vacuum. 
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RESULTS AND DISCUSSIONS 
Isolation of Plasmid DNA 
Plasmid DNA was isolated from E.coli, using Mini preparation (Mini prep.) 
method. The isolated plasmid DNA was run on 1% agarose gel electrophoresis to check 
the integrity of the plasmid. The isolated plasmid was ~1500 base pair in length and was 
supercoiled in conformation. The plasmid had kanamycin resistance gene to serve as 
selection marker. Picture of gel with plasmid DNA and marker DNA are shown in fig. 8. 
Then plasmid DNA was purified through phenol/chloroform purification method. The 
concentration and purity of plasmid DNA were determined by spectrophotometry as 
given in table: 4. 
      Table-4: Details about the plasmid DNA purified from E.coli. 
 
Concentration (µg/ml) 
 
Purity (260/280) 
 
Purity (230/260) 
1791 1.684 0.824 
 
 
 
Fig. 8: Agarose gel electrophoresis of plasmid DNA (E.coli). 
 
 
 
Lane. 1     Marker DNA 
Lane. 2     Plasmid DNA (2µl) 
Lane. 3     Plasmid DNA (6µl) 
Lane. 4     Plasmid DNA (8µl) 
Lane. 5     Plasmid DNA (10µl) 
      1             2           3            4             5 
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Preparation PLA and PLGA Nanoparticles  
PLA and PLGA micro and nanoparticles were prepared by double solvent 
evaporation method. Then BSA (2.5%) (PI of 4.8) was used as a model protein and 
plasmid DNA (final concentration 1mg/ml) was used as a DNA carrier for evaluation of 
the properties of the microparticles and nanoparticles. The particle size was determined 
by Zeta sizer. Particles which were prepared by sonication for both primary and 
secondary emulsion were in nanometre range. The particle size was varied from 43 nm to 
373nm for PLA polymer and for PLGA polymer the particle size was 113.5 nm to 336 
nm. Respective PDI (polydispersity index) values of the formulations were evaluated. 
Polydispersity index (PDI), a term in polymer chemistry referring to the molecular 
weight distribution of polymers. PDI is the mass average degree of molecular weight to 
the number average degree of molecular weight. Zeta potential is a scientific term 
for electro-kinetic potential (McNaught and Wilkinson, 1997). The significance of zeta 
potential is that its value can be related to the stability of colloidal dispersions. The zeta 
potential indicates the degree of repulsion between adjacent, similarly charged particles 
in dispersion. For molecules and particles that are small enough, a high zeta potential will 
confer stability, i.e. the solution or dispersion will resist aggregation. When the potential 
is low, attraction exceeds repulsion and the dispersion will break and flocculate. So, 
colloids with high zeta potential (negative or positive) are electrically stabilized while 
colloids with low zeta potentials tend to coagulate or flocculate.  
BSA and Plasmid DNA loaded PLA Particles 
Sample 101 was the normal sample in which there was no IAP (BSA/pDNA), the 
particle size was 43 nm. When BSA was added to the particles (sample 102, 103 and 104), 
the size were as 258.3 nm, 196.8 nm and 162.7 nm. The loading efficiency was calculated 
using BCA standard curve for BSA protein by using spectrophotometer as shown in fig. 9. 
The loading efficiency was 58.7%, 69.6% and 82.4% for the samples 102, 103 and 104 
respectively. For sample 104 the loading efficiency was high in this sample the OP: IAP 
ratio was 1:10. Similarly for plasmid DNA, when plasmid DNA was added (sample 105, 
106 and 107), then the particle size were ranged from 194.8nm to 373.2 nm. Then the 
loading efficiency was calculated by spectrophotometrically as shown in fig. 10. The 
loading or encapsulation efficiency for these samples were as 42%, 37.6% and 31.12% 
respectively.  
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Sample 105 was shown high loading efficiency in which the OP:IAP ratio was 1:2.5. The 
detail parameter like particle size, zeta potential, PDI and loading efficiency were shown in 
table 5. 
 
 
Fig. 9: BCA standard graph using BCA
TM 
kit. 
 
Table-5: Fomulation of  PLA nanoparticles with their mean particle size,    
                          PDI (poly dispersity index), zeta potential and loading efficiency. 
  
Sl.No Sample 
Name 
Mean Particle 
Size 
Poly 
dispersity 
index 
(PDI) 
Zeta Potential Loading 
Efficiency (%) 
1 101 42.93 1.000 -24.8 No loading 
2 102 258.3 0.337 -32.7 61.6 
3 103 196.8 0.403 -20.5 69.6 
4 104 162.7 0.465 -24.7 82.4 
5 105 194.8 0.359 -19.5 41.95 
6 106 227.9 0.987 -30.3 37.6 
7 107 373.2 0.241 -19.7 31.12 
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(A) 
 
(B) 
Fig. 10: Loading efficiency of BSA (A) and plasmid DNA (B) in PLA nanoparticles.  
0
10
20
30
40
50
60
70
80
90
100
L
o
a
d
in
g
 e
ff
ic
ie
n
cy
 (
%
) 
Sample name (plasmid DNA) 
        105                           106                            107 
0
10
20
30
40
50
60
70
80
90
100
L
o
a
d
in
g
 e
ff
ic
ie
n
cy
 (
%
) 
Sample name (BSA loading) 
       102                             103                             104 
  Page 26 
 
BSA and Plasmid DNA loaded PLGA Particles 
Sample 201 was the normal sample in which there was no IAP (BSA/pDNA), the 
particle size was 178.6nm. When BSA was added to the particles (sample 202, 203 and 
204), the size were as 335.6 nm, 138.5nm and 113.5nm respectively. The loading 
efficiency was calculated using BCA standard curve for BSA protein by 
spectrophotometer. The loading efficiency were 65.3%, 81.3% and 91.2% for the samples 
202, 203 and 204 respectively as shown in fig. 11 (A). For sample 204 the loading 
efficiency was high in this sample and the OP: IAP ratio was 1:10. Similarly for plasmid 
DNA, when plasmid DNA was added (sample 205, 206 and 207), then the particle size 
were ranged from 276.6nm to 143.9 nm respectively. Then the loading efficiency was 
calculated by spectrophotometrically as shown in fig. 11(B). The encapsulation efficiency 
for these samples were 44.6%, 41.4% and 33.7% respectively. It was shown that sample 
205 had highest loading efficiency in which the OP: IAP ratio was 1:2.5. The detail 
parameters like particle size, zeta potential, PDI and loading efficiency were shown as 
given in table 6. 
Table-6: Fomulation of  PLGA nanoparticles with their mean particle size,    
                     PDI (poly dispersity index), zeta potential and loading efficiency. 
 
Sl.No Sample 
Name 
Mean Particle 
Size  
Poly dispersity 
index (PDI) 
Zeta Potential Loading 
Efficiency 
(%) 
1 201 178.6 0.324 -19.9 No loading 
2 202 335.6 0.356 -19.1 65.28 
3 203 138.5 0.518 -30.1 81.28 
4 204 113.5 0.537 -20.3 91.22 
5 205 276.6 0.989 -18.5 44.6 
6 206 143.9 0.958 -17.7 41.4 
7 207 156.2 0.624 -17.7 33.7 
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(A) 
 
(B) 
Fig. 11: Loading efficiency of BSA (A) and plasmid DNA (B) in PLGA nanoparticles.  
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Size and Potential Study of Particles  
 
Fig. 12.1: Sample 101 showing the size (42.93nm) and potential (-24.8mv)  
 
Fig. 12.2: Sample 102 showing the size (258.3nm) and potential (-32.7mv)  
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Fig. 12.3: Sample 106 showing the size (227.9nm) and potential (-30.3mv)  
 
 
Fig. 12.4: Sample 201 showing the size (178.6nm) and potential (-19.9mv)  
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Fig. 12.5: Sample 203 showing the size (138.5nm) and potential (-30.1mv) 
 
 
Fig. 12.6: Sample 207 showing the size (156.2nm) and potential (-17.7mv) 
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In vitro Release Study 
The physico-chemical properties of the stabilizer added seem to affect the release profile 
significantly. The protein and DNA diffusion was expected due to the porous network 
like structure formed in particles during lyophilisation process. The viscosity of the 
solution inside the particles increase due to hydration of the of the polymer chains. Here 
sucrose was used as a stabilizer, which reduced the release rate of protein (Tunon et al., 
2003). The basic salt like NaHCO3 can reduce the acidic effect produced during the 
catalyzed degradation of polymer. Depending upon the types and quantity of stabilizer, 
drug solubilisation via changes in internal matrix pH, rate and extent of matrix hydration 
and polymer erosion can be demonstrated (Chambina  et al., 2004). The release profile of 
these particles showed a biphasic pattern of protein and DNA release. Within first hour, 
the antigen is released as burst release and gradually the rate of release decreases. For 
smaller particles, a large number of antigen accumulated on the surface resulting in a 
greater initial burst release (Rin et al., 2005). 
 
In vitro protein release study 
The particles with stabilizers have an extended and slow release profile. The serum 
albumins added along with sucrose as stabilizer provides a hydrophobic layer around the 
aqueous droplet containing the protein during emulsification process. This provides a 
hydrophobic barrier which shields the active protein from DCM (Dichloromethane). The 
conformational change was brought about by the albumin molecules towards the surface 
of the droplet that forms a hydrophobic layer around the droplet and stabilizes the 
suspension. It not only protects the protein from denaturation (Duncan et al., 1996), but 
also leads to the formation of stable primary emulsion. Within a period of one week, 
PLGA nanoparticles released almost 100% of the encapsulated proteins. There was an 
extended release of the protein with the adding of stabilizers. In case of PLGA 
nanoparticles, more than 56% of the encapsulated protein was released as burst release 
and after 6 hours more than 89% entrapped protein was released. In case of PLA 
nanoparticles, only 42% of encapsulated protein was released in the first burst release 
and after 6 hours around 70% of the entrapped protein released in vitro as given in 
Fig.13. Some similar results were obtained by Nayak et al., 2008. 
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Fig. 13: In vitro protein (BSA) release from encapsulated particles. 
 
In vitro plasmid DNA release study  
Within a period of four days study, PLGA nanoparticles released almost 75% of the 
encapsulated plasmid DNA. There was an extended release of the plasmid DNA with the 
adding of stabilizers. In case of PLGA nanoparticles, more than 27% of the encapsulated 
DNA was released as burst release and after 6 hours more than 46% entrapped pDNA 
was released. In case of PLA nanoparticles, only 20% of encapsulated pDNA was 
released in the first burst release and after 6 hours around 39% of the entrapped protein 
released in vitro as shown in fig. 14. Zou et al., 2009, had described similar results. 
 
 
  Fig. 14: In vitro plasmid DNA release from encapsulated particles 
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Surface Characterization by SEM 
The morphology of these PLA and PLGA particles were spherical structures as 
determined using scanning electron microscope (SEM) as shown in fig. 15. Fig. 15(A) is 
the structure of PLA particles whereas fig. 15(B) is the structure of PLGA particles. The 
surface of the particles are rough and rounded that possesses pores of varying size. It was 
reported that, when the ratio of the IAP to EAP was increased, the relative size of the 
pores increased. 
 
Fig.15(A): SEM structure of PLA nanoparticles. 
 
Fig. 15(B): SEM structure of PLGA nanoparticles 
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